Clinical trial · no report yet · Phase 3
IsKia
Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)
- NCT04483739 ↗
- Active not recruiting
- European Myeloma Network B.V.
- 85 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 46 | |
| YouTube | 24 | |
| Podcasts | 15 |
The trial
ClinicalTrials.gov- Official title
- Phase III Study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) Versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib Lenalidomide Dexamethasone; Isatuximab Carfilzomib Lenalidomide Dexamethasone
- Arms
- Krd Induction · Experimental
- Isa-KRd induction · Experimental
- KRd post ASCT consolidation · Experimental
- Isa-KRd post ASCT consolidation: · Experimental
- KRd light consolidation · Experimental
- Isa-KRd light consolidation · Experimental
- Enrollment
- 302
- Primary outcomes
- Rate of MRD negativity after ASCT consolidation treatment by NGS
- Sponsor
- European Myeloma Network B.V. with EMN Trial Office S.r.l. Impresa Sociale, Sanofi, Amgen
- Start
- Sep 25, 2020
- Primary completion
- Jul 31, 2025
- Results posted
- No
- Registry record
- NCT04483739 · updated Jul 16, 2026
Publications
linked from the registry- Gay F, Roeloffzen W, Dimopoulos MA, Rosinol L, van der Klift M, Mina R, Oriol A, Katodritou E, Wu KL, Rodriguez Otero P, Hajek R, Antonioli E, van Duin M, D'Agostino M, Martinez-Lopez J, van Leeuwen-Segarceanu EM, Zamagni E, van de Donk NWCJ, Weisel KC, Pour L, Radocha J, Belotti A, Schjesvold F, Blade J, Einsele H, Sonneveld P, Boccadoro M, Broijl A. Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial. Nat Med. 2026 May;32(5):1773-1782. doi: 10.1038/s41591-026-04282-0. Epub 2026 Apr 6. PubMed 41942646